Pfizer Forms Research Collaboration With Debiopharm
Pfizer and Debiopharm have entered into a co-development agreement to conduct a phase 3 trial of Tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody, for the treatment of
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).